ArticleAntimicrobial agents and chemotherapy2012
Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 1 synthesis or guideline pooled it, 283 citations in OpenAlex.
- Fusarium species,Scedosporium species, and Lomentospora prolificans: A systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Management, Outcomes, and Factors Associated With Mortality and Treatment Failure of Non-Open forum infectious diseases · 2026Article
- Amphotericin B Resistance inbioRxiv : the preprint server for biology · 2026Article
- Fatal cerebral scedosporiosis in a liver transplant recipient: Diagnostic pitfalls and antifungal resistance.Medical mycology case reports · 2026Article
- Eumycetoma Caused by Acremonium Species in a Farmer From Western Guatemala: A Case Report.Cureus · 2026Article
- Scedosporium apiospermum endocarditis in an immunocompetent patient: a case report and literature review.Journal of cardiothoracic surgery · 2026Review
- A review on clinical cases of rare mold infections and their antifungal treatment strategies.Frontiers in microbiology · 2026Review
- Article
- Pulmonary Infiltrates in a Non-Cystic Fibrosis Bronchiectasis Patient: A Case Report.Journal of clinical medicine · 2025Article
- Redo bilateral lung transplantation in a previous heart-lung transplant recipient for invasive pulmonary scedosporiosis.JHLT open · 2025Article
- Clinical significance and antifungal susceptibility profile of 103 clinical isolates ofJournal of clinical microbiology · 2025Article
- Clinical Significance and Therapeutic Challenges ofJournal of fungi (Basel, Switzerland) · 2025Article
- Diagnosis and management of invasive fungal infections due to non-Aspergillus moulds.The Journal of antimicrobial chemotherapy · 2025Review
- Clinical characterization of immunocompetent patients withRespiratory medicine case reports · 2025Article
- Case report: co-infection ofAME case reports · 2025Article
- First Report ofInfection and drug resistance · 2025Article
- Article
- The Brief Case: Hidden in plain sight-Journal of clinical microbiology · 2024Review
- Review of the novel antifungal drug olorofim (F901318).BMC infectious diseases · 2024Review
- Clinical features and antifungal treatment of invasive Scedosporium boydii infection: report of a case and literature overview.Annals of clinical microbiology and antimicrobials · 2024Review
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the separation of Pseudallescheria boydii and P. apiosperma in 2010, limited data on species-specific susceptibility patterns of these and other species of Pseudallescheria and its anamorph Scedosporium have been reported. This study presents the antifungal susceptibility patterns of members affiliated with both entities. Clinical and environmental isolates (n = 332) from a wide range of sources and origins were identified down to species level and tested according to CLSI M38-A2 against eight antifungal compounds. Whereas P. apiosperma (geometric mean MIC/minimal effective concentration [MEC] values of 0.9, 2.4, 7.4, 16.2, 0.2, 0.8, 1.5, and 6.8 μg/ml for voriconazole, posaconazole, isavuconazole, itraconazole, micafungin, anidulafungin, caspofungin, and amphotericin B, respectively) and P. boydii (geometric mean MIC/MEC values of 0.7, 1.3, 5.7, 13.8, 0.5, 1.4, 2.3, and 11.8 μg/ml for voriconazole, posaconazole, isavuconazole, itraconazole, micafungin, anidulafungin, caspofungin, and amphotericin B, respectively) had similar susceptibility patterns, those for S. aurantiacum, S. prolificans, and S. dehoogii were different from each other. Voriconazole was the only drug with significant activity against S. aurantiacum isolates. The MIC distributions of all drugs except voriconazole did not show a normal distribution and often showed two subpopulations, making a species-based prediction of antifungal susceptibility difficult. Therefore, antifungal susceptibility testing of all clinical isolates remains essential for targeted antifungal therapy. Voriconazole was the only compound with low MIC values (MIC(90) of ≤ 2 μg/ml) for P. apiosperma and P. boydii. Micafungin and posaconazole showed moderate activity against the majority of Scedosporium strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.